April 27, 2022 09:50 AM EDTUpdated 10:03 AM
FDA+
Manufacturing

Fen­nec looks for FDA ap­proval for hear­ing loss drug haunt­ed by man­u­fac­tur­ing prob­lems

Lei Lei Wu

News Reporter

Third time’s the charm. Maybe.

Fen­nec Phar­ma­ceu­ti­cals an­nounced this morn­ing that the FDA is re­view­ing its NDA for its on­ly can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times